US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Bicara Therapeutics Inc. - Common Stock
(NQ:
BCAX
)
17.63
-0.57 (-3.13%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bicara Therapeutics Inc. - Common Stock
< Previous
1
2
3
Next >
Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results
↗
May 23, 2025
Via
Benzinga
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
↗
May 23, 2025
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.
Via
Investor's Business Daily
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
May 23, 2025
Via
Benzinga
Discover the top movers in Friday's pre-market session.
↗
May 23, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
May 23, 2025
Via
Benzinga
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
May 22, 2025
Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday
↗
May 16, 2025
Via
Benzinga
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
April 28, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
April 17, 2025
Via
Benzinga
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 27, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
March 25, 2025
Via
Benzinga
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
March 25, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
February 11, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
January 27, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
↗
January 17, 2025
Via
Benzinga
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
December 09, 2024
Via
Benzinga
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
November 11, 2024
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
↗
October 08, 2024
Via
Benzinga
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
October 08, 2024
Via
Benzinga
StandardAero Surges In Market Debut
↗
October 06, 2024
Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at...
Via
Talk Markets
Topics
Initial Public Offering
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 16, 2024
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Trio Of Biotech IPOs Climb In Debut
↗
September 15, 2024
A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public...
Via
Talk Markets
< Previous
1
2
3
Next >
